Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092632 | 0.93 | MET (0.90) | AXLMET | |
| SCHEMBL16089945 | 0.92 | MET (1.00) | AXLMET | |
| SCHEMBL16089994 | 0.92 | MET (0.88) | AXLMET | |
| SCHEMBL16939063 | 0.90 | MET (0.84) | AXLMET | |
| SCHEMBL17745571 | 0.90 | AXL (0.81) | AXLMET | |
| SCHEMBL16090003 | 0.89 | MET (1.00) | AXLMET | |
| SCHEMBL16089883 | 0.89 | MET (0.86) | AXLMET | |
| SCHEMBL16089998 | 0.87 | MET (0.86) | AXLMET | |
| SCHEMBL16090006 | 0.87 | MET (1.00) | AXLMET | |
| SCHEMBL16089886 | 0.86 | MET (1.00) | AXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-3045453-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885MET 5/4885 |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, FLT3 | AXL 1/4885MET 5/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885MET 5/4885 |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | AXL, RET, FLT3 | AXL 1/4885MET 5/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885MET 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.